PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24456746-5	2014	Blockade of CysLT1R by repeated treatment with montelukast (1 or 2 mg/kg, ig, 4 weeks) reduced Abeta1-42-induced CysLT1R expression and also suppressed Abeta1-42-induced increments of NF-kappaB p65, TNF-alpha, IL-1beta and caspase-3 activation, and Bcl-2 downregulation in the hippocampus and cortex.	montelukast	47-58	interleukin 1 beta	Mus musculus	210-218	
28178069-5	2017	In the present study, our results showed that treatment with montelukast could protect DA neurons against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity and its administration significantly attenuated the production of neurotoxic cytokines such as tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta) from activated microglia in the substantia nigra (SN) and striatum following 6-OHDA treatment.	montelukast	61-72	interleukin 1 beta	Mus musculus	293-310	
24141567-9	2014	Pretreatment of hCysLT1R-BV2 cells with the selective CysLT1R antagonist montelukast (1 mumol/L) significantly blocked LTD4-induced phagocytosis as well as the mRNA expression and release of IL-1beta, whereas the selective CysLT2R antagonist HAMI 3379 (1 mumol/L) had no such effects.	montelukast	73-84	interleukin 1 beta	Mus musculus	191-199